ArticleEJHaem2022
Targetable alterations in primary extranodal diffuse large B-cell lymphoma.
Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- MYD88L265P mutation is a highly specific marker for the nonGCB/ABC DLBCL molecular subtype.Virchows Archiv : an international journal of pathology · 2026Article
- CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.Blood cancer journal · 2025Article
- EFNB1 levels determine distinct drug response patterns guiding precision therapy for B-cell neoplasms.iScience · 2024Article
- Asian variant intravascular large B-cell lymphoma with highly suspected central nervous system involvement: A case report.World journal of clinical cases · 2023Article
- Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review.International journal of molecular sciences · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary extranodal diffuse large B-cell lymphoma (PE-DLBCL) is a heterogeneous subgroup of DLBCL. We investigated the prevalence and prognostic value of surface expression of PD-L1, PD1, and CD30, copy number of 9p24.1 (PD-L1 region), and mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.